
|Articles|September 16, 2004
'PSA era is over in the United States,' leading researcher says
PSA has lost its value as a screening tool for prostate cancer and does nothing more than indicate the size of the prostate gland, according to a study led by Thomas A. Stamey, MD, and published in the October issue of the Journal of Urology (2004; 172:1297-1301).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
Optimizing care for men with overactive bladder, with Keith Xavier, MD
4
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
5






